Greenwich Lifesciences Inc (GLSI)

$9.99 +0.80 (8.71%)
Market Cap 125.26M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 85,400
Avg Vol 69,498
Day's Range N/A - N/A
Shares Out 13.63M
Stochastic %K 56%
Beta 1.62
Analysts Strong Sell
Price Target $42.00

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 832-819-3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
Nherring
Nherring Oct. 24 at 7:40 PM
$GLSI bro this had such high volume and good trading volumes and it just stopped trading - love the stock tho - in master snehal we trust
0 · Reply
rag2riches
rag2riches Oct. 24 at 7:07 PM
$GLSI cant believe its been 5 years ago i saw this stock run from 5 to 150 in a day. When is the interim analysis for the phase 3 expected ? Ai report said that back in 2021 that the IA is expected approx 3 years...
1 · Reply
skiddy5
skiddy5 Oct. 24 at 6:32 PM
$GLSI holy desperation covering on that 8.90 level. I was waiting for mid 8s. Bears are fooked. Time is ticking to cover.
0 · Reply
Alwaysdiversify
Alwaysdiversify Oct. 24 at 6:20 PM
$GLSI Agree, albeit they better get cracking. I am looking forward to seeing the short interest at 10/15. The 9/30 figure of 1.37 million shares is 16X the last 10-day average volume. And, only 30K shares available to borrow when I checked a few minutes ago. Squeeze City......
1 · Reply
albert88
albert88 Oct. 24 at 5:20 PM
$GLSI Back to 10 and up further.
0 · Reply
GLSIforthewin
GLSIforthewin Oct. 24 at 5:18 PM
$GLSI skyrockets in flight! Afternoon delight!
0 · Reply
Gulfoil
Gulfoil Oct. 24 at 4:43 PM
$GLSI going back to double digits….
0 · Reply
Gulfoil
Gulfoil Oct. 24 at 3:03 PM
$GLSI my inkling is shorts will start to get out……they dont have a lot of runway……imo
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Oct. 23 at 3:26 PM
$GLSI Nope. Not true. They are their own CRO. They can “take their time” combing through data and “cleaning it up” so as to present the data at their own timing. Besides- they release it prefer my on Phase 2 in 2020. I hope shorts don’t cover and hope they keep shorting. Astral Projection isn’t a Short’s best friend.
2 · Reply
CLT123
CLT123 Oct. 23 at 3:13 PM
$GLSI there won’t be IA data at SABCS. That’s material and the company would have to PR top line data with full presentation at SABCS. If they had it in time for an LBA submission, we would’ve seen a PR.
1 · Reply
Latest News on GLSI
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Oct 9, 2025, 6:00 AM EDT - 16 days ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Oct 2, 2025, 6:00 AM EDT - 23 days ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 30, 2025, 6:00 AM EDT - 25 days ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 18, 2025, 6:00 AM EDT - 5 weeks ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Sep 10, 2025, 6:00 AM EDT - 6 weeks ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 20, 2025, 9:25 AM EDT - 2 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 19, 2025, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 13, 2025, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Aug 11, 2025, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 7 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 7 months ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Jan 17, 2025, 8:20 AM EST - 10 months ago

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 10 months ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 11 months ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Jun 26, 2024, 2:05 PM EDT - 1 year ago

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 3 years ago

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Dec 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 6, 2022, 5:40 PM EDT - 3 years ago

Greenwich LifeSciences: Persevering CEO And Interesting Data

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Aug 11, 2022, 10:30 AM EDT - 3 years ago

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Aug 3, 2022, 8:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Jul 28, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Jul 12, 2022, 1:18 PM EDT - 3 years ago

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Jul 12, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Jul 11, 2022, 4:15 PM EDT - 3 years ago

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

May 23, 2022, 7:00 AM EDT - 3 years ago

Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

May 23, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences: A First Look

May 19, 2022, 11:12 AM EDT - 3 years ago

Greenwich LifeSciences: A First Look

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Apr 21, 2022, 8:55 AM EDT - 3 years ago

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Apr 20, 2022, 6:10 AM EDT - 3 years ago

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Apr 19, 2022, 6:21 AM EDT - 3 years ago

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Mar 3, 2022, 9:19 AM EST - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Feb 3, 2022, 6:00 AM EST - 4 years ago

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Feb 1, 2022, 6:00 AM EST - 4 years ago

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Nherring
Nherring Oct. 24 at 7:40 PM
$GLSI bro this had such high volume and good trading volumes and it just stopped trading - love the stock tho - in master snehal we trust
0 · Reply
rag2riches
rag2riches Oct. 24 at 7:07 PM
$GLSI cant believe its been 5 years ago i saw this stock run from 5 to 150 in a day. When is the interim analysis for the phase 3 expected ? Ai report said that back in 2021 that the IA is expected approx 3 years...
1 · Reply
skiddy5
skiddy5 Oct. 24 at 6:32 PM
$GLSI holy desperation covering on that 8.90 level. I was waiting for mid 8s. Bears are fooked. Time is ticking to cover.
0 · Reply
Alwaysdiversify
Alwaysdiversify Oct. 24 at 6:20 PM
$GLSI Agree, albeit they better get cracking. I am looking forward to seeing the short interest at 10/15. The 9/30 figure of 1.37 million shares is 16X the last 10-day average volume. And, only 30K shares available to borrow when I checked a few minutes ago. Squeeze City......
1 · Reply
albert88
albert88 Oct. 24 at 5:20 PM
$GLSI Back to 10 and up further.
0 · Reply
GLSIforthewin
GLSIforthewin Oct. 24 at 5:18 PM
$GLSI skyrockets in flight! Afternoon delight!
0 · Reply
Gulfoil
Gulfoil Oct. 24 at 4:43 PM
$GLSI going back to double digits….
0 · Reply
Gulfoil
Gulfoil Oct. 24 at 3:03 PM
$GLSI my inkling is shorts will start to get out……they dont have a lot of runway……imo
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Oct. 23 at 3:26 PM
$GLSI Nope. Not true. They are their own CRO. They can “take their time” combing through data and “cleaning it up” so as to present the data at their own timing. Besides- they release it prefer my on Phase 2 in 2020. I hope shorts don’t cover and hope they keep shorting. Astral Projection isn’t a Short’s best friend.
2 · Reply
CLT123
CLT123 Oct. 23 at 3:13 PM
$GLSI there won’t be IA data at SABCS. That’s material and the company would have to PR top line data with full presentation at SABCS. If they had it in time for an LBA submission, we would’ve seen a PR.
1 · Reply
Alwaysdiversify
Alwaysdiversify Oct. 23 at 1:33 PM
$GLSI Anyone else happen to notice that $41K that has been sitting on the Bid at $8.90 since yesterday afternoon? I see it is still there this morning.
1 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Oct. 23 at 11:19 AM
$GLSI When will late breaking abstract be known at SABCS ?
4 · Reply
mshah1615
mshah1615 Oct. 23 at 12:27 AM
$GLSI
0 · Reply
steveMero
steveMero Oct. 22 at 11:20 PM
$GLSI Mr Patel will flee to India after Mr Trump tariff 100% .
0 · Reply
Hinthint
Hinthint Oct. 22 at 10:58 PM
$GLSI Just saw a segment on CBS News on clinical trials targeting "sleeper cells" that prevents breast cancer reassurance. It is showing lots of promise. Competition? https://whyy.org/articles/sleeper-dormant-breast-cancer-cells/
1 · Reply
pjapak
pjapak Oct. 22 at 7:10 PM
$GLSI Head and double shoulders. 😆😂🤣. Expecting a little more downside.
0 · Reply
Cliffhangers
Cliffhangers Oct. 22 at 7:06 PM
$GLSI Now it's the time to add.
0 · Reply
Gulfoil
Gulfoil Oct. 22 at 4:22 PM
$GLSI same…added.
1 · Reply
Waterwing
Waterwing Oct. 22 at 4:09 PM
$GLSI added...
0 · Reply
Cliffhangers
Cliffhangers Oct. 21 at 6:28 PM
$GLSI @msgbrdinfo Snehal's been refrained from share dilustion thru public offering so far. Snehal is not the type of CEO screwing share holders around with excessive offering and a fat pay check for himself. I actually don't mind a last round of public offering for now. I don't think it will drive the SP down. On the contrary, I see share price going up as the the trial funding is fully secured. But who knows, there maybe ATM ongoing or a private debt credit, or a collaborative agreement with fund injection. Should that happen, the train would already leave the station. So make sure you are on board.
0 · Reply
msgbrdinfo
msgbrdinfo Oct. 21 at 6:14 PM
$GLSI There are a few of you here who seem to know a lot about shorts. Does this last 4 days of shorting look like a lot of short activity to you? I do see the total short vol is like 20% of the float! Correct? I think when Q3 numbers are out in around 3+ weeks, we can see cash flow numbers and see if the ATM printing press was active up to Oct 1st. Just curious what is going on. Regardless, it looks like a good time to add shares.
0 · Reply
Cliffhangers
Cliffhangers Oct. 21 at 4:48 PM
$GLSI The first patient was treated end of 2022. What matters is not the first patient, but when the statistically significant sample size are treated for 1.5-2 yrs. Until then, IA will start. Give it another yr or so. But should you sell and hope to get a lower entry price later? Absolutely no! Things could happen even before IA: a collaborative deal, a licensing deal, etc.. You sure don't wanna miss out...
0 · Reply